FIRST PATIENTS ENROLLED IN THE GORE VBX FORWARD CLINICAL STUDY
/PRNewswire/ -- W. L. Gore & Associates, Inc. (Gore) announced today that the first patients have been enrolled in the Gore VBX FORWARD Clinical Study...
Stay updated with breaking news from Inc Mpd Division. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- W. L. Gore & Associates, Inc. (Gore) announced today that the first patients have been enrolled in the Gore VBX FORWARD Clinical Study...
/PRNewswire/ -- W. L. Gore & Associates (Gore) announces that patients have passed through the multi-month enhanced screening process and have begun entering...
/PRNewswire/ -- W. L. Gore & Associates (Gore) has announced that the first U.S. patient has been enrolled in a prospective, non-randomized, multicenter,...
/PRNewswire/ -- W. L. Gore & Associates (Gore) announced today that it is initiating the RELIEF Clinical Study – an investigational study to evaluate the...
(1) and surgeons need a high-quality material for hernia repair in complex patients (VHWG 2). (2) FLAGSTAFF, Ariz., Feb. 22, 2021 /PRNewswire/ -- W. L. Gore & Associates (Gore) announced that GORE SYNECOR Intraperitoneal Biomaterial is now available in Europe, Middle East and South Africa. The device was designed to address unmet needs in complex hernia repair, providing rapid vascularity 3 and permanent strength with a low profile for single, effective hernia repair. GORE® SYNECOR Intraperitoneal Biomaterial offers a tri-layer hybrid solution that supports single, effective hernia repair in...